GlassScriptPhysician profile
Wynn Boyle
NPI 1235298654
$2,231.87
in general payments reported to CMS, 2019-2025
30 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $615 · 2023: $431 · 2024: $459 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $454.68 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Xeris Pharmaceuticals, INC. | $335.81 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $190.99 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.78 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $146.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $146.10 | 2022-2023 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $71.63 | 2023-2024 | Veozah |
| Dexcom, INC. | $66.49 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $65.03 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $58.08 | 2023 | Shingrix, Arexvy, Bexsero |
| Lifescan, INC. | $56.14 | 2021-2022 | |
| Abbvie INC. | $54.69 | 2021-2025 | |
| Amphastar Pharmaceuticals, INC. | $45.43 | 2025 | |
| Esperion Therapeutics, INC. | $44.05 | 2025 | Nexletol |
| Amgen INC. | $37.09 | 2024 | Evenity, Prolia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $30.40 | 2021-2024 | Omnipod |
| Pfizer INC. | $29.08 | 2025 | |
| Sanofi US Services INC. | $25.86 | 2024 | |
| Hologic Sales and Service, LLC | $25.71 | 2024 | Aptima |
| Atricure, INC. | $22.22 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $22.16 | 2023 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $19.85 | 2024 | |
| Corcept Therapeutics | $19.57 | 2023 | Korlym |
| Seqirus USA INC | $18.68 | 2024 | Flucelvax, Fluad |
| Biohaven Pharmaceuticals, INC. | $16.67 | 2021 | |
| Beta Bionics, INC. | $16.32 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ibsa Pharma INC. | $14.32 | 2023 | Tirosint, Licart |
| Inspire Medical Systems, INC. | $13.99 | 2025 | Inspire |
| Medtronic, INC. | $12.11 | 2022 | |
| Mannkind Corporation | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wynn Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.